<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>419</ReferenceId>
        <DateLastUpdated>2020-10-11-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15710907</PubmedId>
            <Abstract>MUC1 mucin is expressed by normal human epithelial cells and is overproduced in underglycosylated form by malignant epithelial cells. A number of anticancer immunotherapeutic strategies are being designed with the goal of inducing humoral and cellular immune responses against MUC1 mucin. Newly synthesized MUC1 mucin is also expressed on polyclonally stimulated human T cells. An immunoregulatory role has been postulated for MUC1 mucin expressed by activated T cells. We now show that several MUC1 peptide and glycopeptide epitope specific antibodies bind to activated T cells and inhibit their proliferation. Inhibition by antibody B27.29 could be reversed by glycopeptide haptens specific for the antibody. Intact antibody B27.29 and its divalent F(ab')(2) fragment inhibited the proliferation of T cells undergoing T cell activation but the monovalent Fab' fragment did not, indicating that cross-linking of the MUC1 antigen on T cells is required for the inhibitory effect. MUC1 expression on activated T cells was increased in the presence of IL-12 but was not affected by IFN-gamma, IL-2, IL-4, IL-5, IL-10, IL-13 or TNF-alpha. Treatment of T cells inhibited by monoclonal antibody (MAb) B27.29 with either IL-2 or costimulatory anti-CD28 antibody restored proliferation to a level equivalent to that of control cultures. These results provide further support for the hypothesis that the expression of MUC1 on the activated T cell surface is associated with the regulation of T cell responses.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>391-9</ArticlePages>
            <ArticleTitle>MUC1 mucin-mediated regulation of human T cells.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Agrawal</LastName>
                    <ForeName>Babita</ForeName>
                </Author>
                <Author>
                    <LastName>Longenecker</LastName>
                    <ForeName>B Michael</ForeName>
                </Author>
            </Authors>
            <Affiliations>611-Heritage Medical Research Centre, Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, T6G 2S2, Canada. bagrawal@ualberta.ca</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Antigens, CD;Antigens, Differentiation, T-Lymphocyte;CD69 antigen;Cytokines;Epitopes, T-Lymphocyte;Glycopeptides;Haptens;Lectins, C-Type;Mucin-1;Receptors, Interleukin-2</ArticleChemicalList>
            <ArticleMeshHeadingsList>Antibodies, Monoclonal(immunology); Antigens, CD(immunology); Antigens, Differentiation, T-Lymphocyte(immunology); Cell Proliferation; Cytokines(metabolism); Epitopes, T-Lymphocyte(immunology); Glycopeptides(immunology); Haptens(immunology); Humans; Lectins, C-Type; Lymphocyte Activation(immunology); Mucin-1(immunology); Receptors, Interleukin-2(immunology); T-Lymphocytes(immunology; metabolism)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>17</Volume>
                <Issue>4</Issue>
                <Title>International immunology</Title>
                <Issn>1460-2377</Issn>
                <MedlineTa>Int Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Glycopeptide 6GVT(3Tn)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GVTSAPDTRPAPGSTA</LinearSequence>
                        <ModifiedResidues>T3</ModifiedResidues>
                        <Modifications>Glycosylation</Modifications>
                        <StartingPosition>137</StartingPosition>
                        <EndingPosition>152</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAB53150.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Methods</LocationOfData>
                <EpitopeId>23179</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>Glycosylation is alpha-GalNac.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1, Figures 1, 2 and 5</LocationOfData>
                        <BCellId>18396</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAB53150.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Partially purified mucin fraction</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>B27.29 MAb was raised against partially purified mucin fraction derived from ascites fluid of a cancer patient.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb bound to activated T cells and inhibited their proliferative response. Both the intact mAb and the divalent F(ab')2 fragment were inhibitory, while the monovalent Fab' fragment was not, implying cross-linking of the antigen on the cells surface was required. The addition of a cross-linking anti-mouse Fc goat secondary antibody to the cells incubated with the intact epitope-specific mAb enhanced the inhibition of proliferation confirming the hypothesis of cross-linking needed for the inhibitory effect. Co-stimulation with anti-CD28 mAb or IL-2 at the beginning of and 72 hours post-initiation of culture reversed MUC1 cross-linking mediated inhibition of T-cell proliferation.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>B27.29 Anti-MUC1 Ab</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Activated T cells</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                <Object>
                                    <DerivativeOfOrganism>
                                        <SubType>Cell</SubType>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </DerivativeOfOrganism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1, Figures 3 and 4</LocationOfData>
                        <BCellId>18397</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAB53150.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Partially purified mucin fraction</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>B27.29 MAb was raised against partially purified mucin fraction derived from ascites fluid of a cancer patient.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>139</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb bound to human peripheral blood T lymphocytes previously stimulated with anti-CD3 or PHA to display an activated phenotype, implying that the antigen MUC1 is upregulated during the activation. The effect of of cytokines IFN-g, IL-2, IL-4, IL-5, IL-10, IL-12, IL-13 and TNF-a on MUC1 expression on activated T cells showed that only IL-12 induced upregulation of the MUC1 expression as shown by FACS with the epitope-specific mAb.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>B27.29 Anti-MUC1 Ab</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Activated T cells</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                <Object>
                                    <DerivativeOfOrganism>
                                        <SubType>Cell</SubType>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </DerivativeOfOrganism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <BCellId>2186</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAB53150.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Partially purified mucin fraction</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>B27.29 MAb was raised against partially purified mucin fraction derived from ascites fluid of a cancer patient.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>144</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Preincubation of the epitope-specific mAb with the epitope inhibited the anti-proliferative effect of the mAb on human peripheral blood T lymphocytes stimulated with anti-CD3.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>B27.29 Anti-MUC1 Ab</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GVTSAPDTRPAPGSTA</LinearSequence>
                                        <ModifiedResidues>T3</ModifiedResidues>
                                        <Modifications>Glycosylation</Modifications>
                                        <StartingPosition>137</StartingPosition>
                                        <EndingPosition>152</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAB53150.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Glycopeptide 6GVT(4Tn)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GVTSAPDTRPAPGSTA</LinearSequence>
                        <ModifiedResidues>S4</ModifiedResidues>
                        <Modifications>Glycosylation</Modifications>
                        <StartingPosition>137</StartingPosition>
                        <EndingPosition>152</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAB53150.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Methods</LocationOfData>
                <EpitopeId>23178</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>Glycosylation is alpha-GalNac.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1, Figures 1, 2 and 5</LocationOfData>
                        <BCellId>18398</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAB53150.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Partially purified mucin fraction</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>B27.29 MAb was raised against partially purified mucin fraction derived from ascites fluid of a cancer patient.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb bound to activated T cells and inhibited their proliferative response. Both the intact mAb and the divalent F(ab')2 fragment were inhibitory, while the monovalent Fab' fragment was not, implying cross-linking of the antigen on the cells surface was required. The addition of a cross-linking anti-mouse Fc goat secondary antibody to the cells incubated with the intact epitope-specific mAb enhanced the inhibition of proliferation confirming the hypothesis of cross-linking needed for the inhibitory effect. Co-stimulation with anti-CD28 mAb or IL-2 at the beginning of and 72 hours post-initiation of culture reversed MUC1 cross-linking mediated inhibition of T-cell proliferation.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>B27.29 Anti-MUC1 Ab</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Activated T cells</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                <Object>
                                    <DerivativeOfOrganism>
                                        <SubType>Cell</SubType>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </DerivativeOfOrganism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1, Figures 3 and 4</LocationOfData>
                        <BCellId>18399</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAB53150.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Partially purified mucin fraction</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>B27.29 MAb was raised against partially purified mucin fraction derived from ascites fluid of a cancer patient.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>139</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb bound to human peripheral blood T lymphocytes previously stimulated with anti-CD3 or PHA to display an activated phenotype, implying that the antigen MUC1 is upregulated during the activation. The effect of of cytokines IFN-g, IL-2, IL-4, IL-5, IL-10, IL-12, IL-13 and TNF-a on MUC1 expression on activated T cells showed that only IL-12 induced upregulation of the MUC1 expression as shown by FACS with the epitope-specific mAb.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>B27.29 Anti-MUC1 Ab</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Activated T cells</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                <Object>
                                    <DerivativeOfOrganism>
                                        <SubType>Cell</SubType>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </DerivativeOfOrganism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <BCellId>18311</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAB53150.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Partially purified mucin fraction</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>B27.29 MAb was raised against partially purified mucin fraction derived from ascites fluid of a cancer patient.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>144</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Preincubation of the epitope-specific mAb with the epitope inhibited the anti-proliferative effect of the mAb on human peripheral blood T lymphocytes stimulated with anti-CD3.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>B27.29 Anti-MUC1 Ab</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>MUC 1 hapten 4Tn</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GVTSAPDTRPAPGSTA</LinearSequence>
                                        <ModifiedResidues>S4</ModifiedResidues>
                                        <Modifications>Glycosylation</Modifications>
                                        <StartingPosition>137</StartingPosition>
                                        <EndingPosition>152</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAB53150.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>APDTR</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>APDTR</LinearSequence>
                        <StartingPosition>141</StartingPosition>
                        <EndingPosition>145</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAB53150.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Methods</LocationOfData>
                <EpitopeId>3514</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>18325</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000231</OrganismId>
                                <Sex>F</Sex>
                                <Age>8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                    <Object>
                                        <DerivativeOfOrganism>
                                            <SubType>Product of Organism</SubType>
                                            <DerivativeType>Milk</DerivativeType>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </DerivativeOfOrganism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Human milk fat globule membrane (HMFGM)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses of 200 ug 3-6 week intervals</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The derivation of the epitope-specific mAb is described in Xing et al, Immunol Cell Biol. 1989 67:183 [PMID:2477330]. Mice were immunized i.p with Human milk fat globule membrane (HMFGM) in CFA and then boosted intravenously with 200 ug HMFGM and 100 ul human milk 3 days before fusion.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb bound to activated T cells and inhibited their proliferative response.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>BC3 anti-MUC1 Ab</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Activated T cells</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                <Object>
                                    <DerivativeOfOrganism>
                                        <SubType>Cell</SubType>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </DerivativeOfOrganism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>21032</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000231</OrganismId>
                                <Sex>F</Sex>
                                <Age>8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                    <Object>
                                        <DerivativeOfOrganism>
                                            <SubType>Product of Organism</SubType>
                                            <DerivativeType>Milk</DerivativeType>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </DerivativeOfOrganism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Human milk fat globule membrane (HMFGM)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses of 200 ug 3-6 week intervals</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The derivation of the epitope-specific mAb is described in Xing et al, Immunol Cell Biol. 1989 67:183 [PMID:2477330]. Mice were immunized i.p with Human milk fat globule membrane (HMFGM) in CFA and then boosted intravenously with 200 ug HMFGM and 100 ul human milk 3 days before fusion.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>139</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb bound to human peripheral blood T lymphocytes previously stimulated with anti-CD3 to display an activated phenotype.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>BC3 anti-MUC1 Ab</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Activated T cells</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                <Object>
                                    <DerivativeOfOrganism>
                                        <SubType>Cell</SubType>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </DerivativeOfOrganism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>APDTRPAP</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>APDTRPAP</LinearSequence>
                        <StartingPosition>141</StartingPosition>
                        <EndingPosition>148</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAB53150.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Methods</LocationOfData>
                <EpitopeId>3517</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>18336</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                    <Object>
                                        <DerivativeOfOrganism>
                                            <SubType>Cell</SubType>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </DerivativeOfOrganism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Membrane rich fraction of human metastatic breast carcinoma</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>No further details on the mAb generation could be found.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb bound to activated T cells and inhibited their proliferative response.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>DF3 anti-MUC1 Ab</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Activated T cells</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                <Object>
                                    <DerivativeOfOrganism>
                                        <SubType>Cell</SubType>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </DerivativeOfOrganism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>21036</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                    <Object>
                                        <DerivativeOfOrganism>
                                            <SubType>Cell</SubType>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </DerivativeOfOrganism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Membrane rich fraction of human metastatic breast carcinoma</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>No further details on the mAb generation could be found.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>139</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb bound to human peripheral blood T lymphocytes previously stimulated with anti-CD3 to display an activated phenotype.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>DF3 anti-MUC1 Ab</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Activated T cells</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                <Object>
                                    <DerivativeOfOrganism>
                                        <SubType>Cell</SubType>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </DerivativeOfOrganism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>APDTRP</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>APDTRP</LinearSequence>
                        <StartingPosition>141</StartingPosition>
                        <EndingPosition>146</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAB53150.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Methods</LocationOfData>
                <EpitopeId>3516</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>21037</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAB53150.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hydrogen fluoride deglycosylated milk mucin.</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2 doses of 5 ug 3 months apart.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The epitope-specific mAb generation is described in Burchell et al, Cancer Res. 1987 47:5476 [PMID:2443241]. First dose was in Freund's complete adjuvant and boost in Freund's incomplete adjuvant. After a further 20 days, 5 ug of the deglycosylated mucin was given i.v. in saline solution 4 days before fusion.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>139</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb bound to human peripheral blood T lymphocytes previously stimulated with anti-CD3 to display an activated phenotype.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>SM3 anti-MUC1 Ab</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Activated T cells</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                <Object>
                                    <DerivativeOfOrganism>
                                        <SubType>Cell</SubType>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </DerivativeOfOrganism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>18339</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAB53150.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Hydrogen fluoride deglycosylated milk mucin.</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2 doses of 5 ug 3 months apart.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The epitope-specific mAb generation is described in Burchell et al, Cancer Res. 1987 47:5476 [PMID:2443241]. First dose was in Freund's complete adjuvant and boost in Freund's incomplete adjuvant. After a further 20 days, 5 ug of the deglycosylated mucin was given i.v. in saline solution 4 days before fusion.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb bound to activated T cells and inhibited their proliferative response.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>SM3 anti-MUC1 Ab</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Activated T cells</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                <Object>
                                    <DerivativeOfOrganism>
                                        <SubType>Cell</SubType>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </DerivativeOfOrganism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>TSAPDTRAPAP</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TSAPDTRPAP</LinearSequence>
                        <StartingPosition>139</StartingPosition>
                        <EndingPosition>148</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAB53150.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Methods</LocationOfData>
                <EpitopeId>66161</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>21038</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                    <Object>
                                        <DerivativeOfOrganism>
                                            <SubType>Cell</SubType>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </DerivativeOfOrganism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Human breast tumor cell line T417 membranes</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunization is described in Bray et al, Cancer Res. 1987 47:5853 [PMID:2444335]. No futher details are provided.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>139</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb bound to human peripheral blood T lymphocytes previously stimulated with anti-CD3 to display an activated phenotype.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>BC4E549 anti-MUC1 Ab</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Activated T cells</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                <Object>
                                    <DerivativeOfOrganism>
                                        <SubType>Cell</SubType>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </DerivativeOfOrganism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>18340</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                    <Object>
                                        <DerivativeOfOrganism>
                                            <SubType>Cell</SubType>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </DerivativeOfOrganism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Human breast tumor cell line T417 membranes</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunization is described in Bray et al, Cancer Res. 1987 47:5853 [PMID:2444335]. No futher details are provided.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb bound to activated T cells and inhibited their proliferative response.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>BC4E549 anti-MUC1 Ab</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Activated T cells</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                <Object>
                                    <DerivativeOfOrganism>
                                        <SubType>Cell</SubType>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </DerivativeOfOrganism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Le&lt;sup&gt;x&lt;/sup&gt; trisaccharide</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalNonSequenceMolecule>
                        <ChemicalType>Carbohydrate fragment</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:59294</ChEBIId>
                        </Molecule>
                        <SourceMolecule>
                            <GenBankId>AAB53150.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Methods</LocationOfData>
                <EpitopeId>130654</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>21040</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                    <Object>
                                        <DerivativeOfOrganism>
                                            <SubType>Cell</SubType>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </DerivativeOfOrganism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>LIM 1863 colonic cell line</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <DoseSchedule>5 doses on days 0, 7, 15, 21 and 24.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>First and 2nd doses were in CFA, others in PBS. The immunization is described in Teh et al, Immunol Cell Biol. 1990 68:207 [PMID:1699885]. No further details are provided.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb bound to activated T cells and inhibited their proliferative response.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>DH-1 anti-MUC1 Ab</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Activated T cells</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                <Object>
                                    <DerivativeOfOrganism>
                                        <SubType>Cell</SubType>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </DerivativeOfOrganism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>21039</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                    <Object>
                                        <DerivativeOfOrganism>
                                            <SubType>Cell</SubType>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </DerivativeOfOrganism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>LIM 1863 colonic cell line</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <DoseSchedule>5 doses on days 0, 7, 15, 21 and 24.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>First and 2nd doses were in CFA, others in PBS. The immunization is described in Teh et al, Immunol Cell Biol. 1990 68:207 [PMID:1699885]. No further details are provided.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>139</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb bound to human peripheral blood T lymphocytes previously stimulated with anti-CD3 to display an activated phenotype.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>DH-1 anti-MUC1 Ab</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Activated T cells</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Derivative of Source Organism</EpitopeRelation>
                                <Object>
                                    <DerivativeOfOrganism>
                                        <SubType>Cell</SubType>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </DerivativeOfOrganism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

